Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis

Severa Bunda, Kelly Burrell, Pardeep Heir, Lifan Zeng, Amir Alamsahebpour, Yoshihito Kano, Brian Raught, Zhong-Yin Zhang, Gelareh Zadeh, Michael Ohh

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Ras is phosphorylated on a conserved tyrosine at position 32 within the switch I region via Src kinase. This phosphorylation inhibits the binding of effector Raf while promoting the engagement of GTPase-activating protein (GAP) and GTP hydrolysis. Here we identify SHP2 as the ubiquitously expressed tyrosine phosphatase that preferentially binds to and dephosphorylates Ras to increase its association with Raf and activate downstream proliferative Ras/ERK/MAPK signalling. In comparison to normal astrocytes, SHP2 activity is elevated in astrocytes isolated from glioblastoma multiforme (GBM)-prone H-Ras(12V) knock-in mice as well as in glioma cell lines and patient-derived GBM specimens exhibiting hyperactive Ras. Pharmacologic inhibition of SHP2 activity attenuates cell proliferation, soft-agar colony formation and orthotopic GBM growth in NOD/SCID mice and decelerates the progression of low-grade astrocytoma to GBM in a spontaneous transgenic glioma mouse model. These results identify SHP2 as a direct activator of Ras and a potential therapeutic target for cancers driven by a previously 'undruggable' oncogenic or hyperactive Ras.

Original languageEnglish (US)
Article number8859
JournalNature Communications
Volume6
DOIs
StatePublished - Nov 30 2015

Fingerprint

Glioblastoma
mice
Tyrosine
Carcinogenesis
tyrosine
GTPase-Activating Proteins
Phosphorylation
src-Family Kinases
Cell proliferation
Guanosine Triphosphate
Phosphoric Monoester Hydrolases
Glioma
Astrocytes
Agar
effectors
Hydrolysis
phosphorylation
phosphatases
Cells
Switches

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Chemistry(all)
  • Physics and Astronomy(all)

Cite this

Bunda, S., Burrell, K., Heir, P., Zeng, L., Alamsahebpour, A., Kano, Y., ... Ohh, M. (2015). Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis. Nature Communications, 6, [8859]. https://doi.org/10.1038/ncomms9859

Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis. / Bunda, Severa; Burrell, Kelly; Heir, Pardeep; Zeng, Lifan; Alamsahebpour, Amir; Kano, Yoshihito; Raught, Brian; Zhang, Zhong-Yin; Zadeh, Gelareh; Ohh, Michael.

In: Nature Communications, Vol. 6, 8859, 30.11.2015.

Research output: Contribution to journalArticle

Bunda, S, Burrell, K, Heir, P, Zeng, L, Alamsahebpour, A, Kano, Y, Raught, B, Zhang, Z-Y, Zadeh, G & Ohh, M 2015, 'Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis', Nature Communications, vol. 6, 8859. https://doi.org/10.1038/ncomms9859
Bunda S, Burrell K, Heir P, Zeng L, Alamsahebpour A, Kano Y et al. Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis. Nature Communications. 2015 Nov 30;6. 8859. https://doi.org/10.1038/ncomms9859
Bunda, Severa ; Burrell, Kelly ; Heir, Pardeep ; Zeng, Lifan ; Alamsahebpour, Amir ; Kano, Yoshihito ; Raught, Brian ; Zhang, Zhong-Yin ; Zadeh, Gelareh ; Ohh, Michael. / Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis. In: Nature Communications. 2015 ; Vol. 6.
@article{4699351ab13f4443b1d710060466b63e,
title = "Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis",
abstract = "Ras is phosphorylated on a conserved tyrosine at position 32 within the switch I region via Src kinase. This phosphorylation inhibits the binding of effector Raf while promoting the engagement of GTPase-activating protein (GAP) and GTP hydrolysis. Here we identify SHP2 as the ubiquitously expressed tyrosine phosphatase that preferentially binds to and dephosphorylates Ras to increase its association with Raf and activate downstream proliferative Ras/ERK/MAPK signalling. In comparison to normal astrocytes, SHP2 activity is elevated in astrocytes isolated from glioblastoma multiforme (GBM)-prone H-Ras(12V) knock-in mice as well as in glioma cell lines and patient-derived GBM specimens exhibiting hyperactive Ras. Pharmacologic inhibition of SHP2 activity attenuates cell proliferation, soft-agar colony formation and orthotopic GBM growth in NOD/SCID mice and decelerates the progression of low-grade astrocytoma to GBM in a spontaneous transgenic glioma mouse model. These results identify SHP2 as a direct activator of Ras and a potential therapeutic target for cancers driven by a previously 'undruggable' oncogenic or hyperactive Ras.",
author = "Severa Bunda and Kelly Burrell and Pardeep Heir and Lifan Zeng and Amir Alamsahebpour and Yoshihito Kano and Brian Raught and Zhong-Yin Zhang and Gelareh Zadeh and Michael Ohh",
year = "2015",
month = "11",
day = "30",
doi = "10.1038/ncomms9859",
language = "English (US)",
volume = "6",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis

AU - Bunda, Severa

AU - Burrell, Kelly

AU - Heir, Pardeep

AU - Zeng, Lifan

AU - Alamsahebpour, Amir

AU - Kano, Yoshihito

AU - Raught, Brian

AU - Zhang, Zhong-Yin

AU - Zadeh, Gelareh

AU - Ohh, Michael

PY - 2015/11/30

Y1 - 2015/11/30

N2 - Ras is phosphorylated on a conserved tyrosine at position 32 within the switch I region via Src kinase. This phosphorylation inhibits the binding of effector Raf while promoting the engagement of GTPase-activating protein (GAP) and GTP hydrolysis. Here we identify SHP2 as the ubiquitously expressed tyrosine phosphatase that preferentially binds to and dephosphorylates Ras to increase its association with Raf and activate downstream proliferative Ras/ERK/MAPK signalling. In comparison to normal astrocytes, SHP2 activity is elevated in astrocytes isolated from glioblastoma multiforme (GBM)-prone H-Ras(12V) knock-in mice as well as in glioma cell lines and patient-derived GBM specimens exhibiting hyperactive Ras. Pharmacologic inhibition of SHP2 activity attenuates cell proliferation, soft-agar colony formation and orthotopic GBM growth in NOD/SCID mice and decelerates the progression of low-grade astrocytoma to GBM in a spontaneous transgenic glioma mouse model. These results identify SHP2 as a direct activator of Ras and a potential therapeutic target for cancers driven by a previously 'undruggable' oncogenic or hyperactive Ras.

AB - Ras is phosphorylated on a conserved tyrosine at position 32 within the switch I region via Src kinase. This phosphorylation inhibits the binding of effector Raf while promoting the engagement of GTPase-activating protein (GAP) and GTP hydrolysis. Here we identify SHP2 as the ubiquitously expressed tyrosine phosphatase that preferentially binds to and dephosphorylates Ras to increase its association with Raf and activate downstream proliferative Ras/ERK/MAPK signalling. In comparison to normal astrocytes, SHP2 activity is elevated in astrocytes isolated from glioblastoma multiforme (GBM)-prone H-Ras(12V) knock-in mice as well as in glioma cell lines and patient-derived GBM specimens exhibiting hyperactive Ras. Pharmacologic inhibition of SHP2 activity attenuates cell proliferation, soft-agar colony formation and orthotopic GBM growth in NOD/SCID mice and decelerates the progression of low-grade astrocytoma to GBM in a spontaneous transgenic glioma mouse model. These results identify SHP2 as a direct activator of Ras and a potential therapeutic target for cancers driven by a previously 'undruggable' oncogenic or hyperactive Ras.

UR - http://www.scopus.com/inward/record.url?scp=84948674328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948674328&partnerID=8YFLogxK

U2 - 10.1038/ncomms9859

DO - 10.1038/ncomms9859

M3 - Article

VL - 6

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

M1 - 8859

ER -